Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Non-current Assets
All assets not expected to be converted to cash within one year.
Alumis Inc. Common StockNASDAQ: ALMS
Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Total non-current assets falls 50.2% from a year ago
Total non-current assets stood at $46.53M at the end of Q2 FY2026, down 50.2% from a year earlier and down 66.6% from the prior quarter. Over 3 fiscal years it compounded at +155.6% a year.
Context
- Total non-current assets amounted to 8.3% of total assets at the end of Q2 FY2026, down 7.0 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -50.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 93.71M USD
- Year-over-year change
- +169.2%
- 3-year CAGR
- +155.6%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.71M | +169.2% |
| FY2024 | 2024-12-31 | 34.8M | -4.0% |
| FY2023 | 2023-12-31 | 36.26M | +545.9% |
| FY2022 | 2022-12-31 | 5.61M | — |
Total Non-current Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -50.2% is the 7th highest of 9, against a peer median of -11.8%.
- Total non-current assets amounts to 8.3% of total assets for ALMS, versus a peer median of 16.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $270.58M USD | +820.1% | +146.0% | 53.6% | |
| Mar 2026 | $88.49M USD | -0.9% | -26.6% | 44.5% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $46.53M USD | -50.2% | +155.6% | 8.3% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €32.62M EUR | — | — | 19.7% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $17.22M USD | -19.0% | -13.6% | 16.2% |
| Mar 2026 | $13.58M USD | -77.0% | -55.7% | 4.1% | |
| Mar 2026 | $11.06M USD | -4.5% | -13.0% | 11.1% | |
| Dec 2025 | $2.94M USD | -22.1% | +10.3% | 25.6% | |
| Mar 2026 | €1.49M EUR | +7.6% | -31.8% | 3.1% | |
| Mar 2026 | $209.26K USD | -55.2% | +0.9% | 0.3% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -11.8% | -13.3% | 16.2% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.